◀ Back to MAPK8

CDK2 — MAPK8

Pathways - manually collected, often from reviews:

• NCI Pathway Database p53 pathway: CDK2/Cyclin A complex (CDK2-CCNA2) → JNK1-2-active (MAPK8/MAPK9) (modification, activates)
  Bulavin et al., EMBO J 1999*, Blaydes et al., J Biol Chem 2001*, Buschmann et al., Mol Cell Biol 2001*
  Evidence: mutant phenotype, assay, physical interaction

Text-mined interactions from Literome

Liu et al., Di Yi Jun Yi Da Xue Xue Bao 2002 (Cardiomyopathy, Hypertrophic...) : [ Regulation of cyclin dependent kinase inhibitors by mitogen activated protein kinase in angiotensin II-stimulated vascular smooth muscle cell hypertrophy ] ... To investigate the role of mitogen activated protein kinase ( MAPK ) in the regulation of cyclin dependent kinase inhibitors ( CDKI ) in the process of vascular smooth muscle cell ( VSMC ) hypertrophy induced by angiotensin II stimulation
Corrèze et al., Eur J Endocrinol 2005 : These results indicate that p38 MAPK activity is involved in the regulation of cell cycle progression in FRTL-5 thyroid cells, at least in part by increasing nuclear Cdk2 activity
Lee et al., J Cell Biochem 2006 : In addition, PD 98059 ( a MEK inhibitor ), SB 203580 ( a p38 MAPK inhibitor ), and SP 600125 ( a JNK inhibitor ) blocked the EGF induced stimulation of [ 3H ] -thymidine incorporation and CDK-2/4 expression
Brennan et al., J Med Food 2012 (Adrenocortical Carcinoma) : BME treatment enhanced cellular tumor antigen p53, cyclin dependent kinase inhibitor 1A ( also called p21 ), and cyclic AMP dependent transcription factor-3 levels and inhibited G1/S-specific cyclin D1, D2, and D3, and mitogen activated protein kinase 8 ( also called Janus kinase ) expression, suggesting an additional mechanism involving cell cycle regulation and cell survival